Dr. Sartor on Patients in the ALSYMPCA Radium-223 Trial

Dr. Oliver Sartor, from Tulane Cancer Center, Describes Patients in the ALSYMPCA Radium-223 Trial

Oliver Sartor, MD, medical director, Tulane Cancer Center, describes the patients that were included in the phase III ALSYMPCA trial that examined radium-223 (Alpharadin), an experimental radiopharmaceutical, for symptomatic hormone refractory prostate cancer with skeletal metastases.

The inclusion criteria for the trial resulted in two groups of patients, those that had already received docetaxel and progressed and those deemed unfit to receive docetaxel.

The trial enrolled 922 men that were randomized 2:1 to receive either the current standard of care plus radium-223 or placebo. The experimental arm resulted in a 2.8-month median increase in progression-free survival and an increase of 5.2 months until the first skeletal related event.

Sartor notes that in the US only 55-60% of patients are deemed fit to receive docetaxel. These criteria resulted in a large number of patients being eligible to participate in the ALSYMPCA trial.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine